Vitamins for age-related macular degeneration demonstrate minimal differences.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

1. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.The Cochrane database of systematic reviews · 2023
   Pooled it
2. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.The Cochrane database of systematic reviews · 2017
   Pooled it
3. The Role of Reactive Oxygen Species in Age-Related Macular Degeneration: A Comprehensive Review of Antioxidant Therapies.Biomedicines · 2024
   Review
4. Daily multivitamins to reduce mortality, cardiovascular disease, and cancer.Canadian family physician Medecin de famille canadien · 2013
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as